The Patent Finder

Chimerix, Inc.

9 patents currently held · Updated Nov 21, 2026
24 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
1
Ending by 2030
Sep 2030
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Mar 10, 2027
    The maintenance fee for Pyrrolopyrimidine Nucleosides and Analogs Thereof (US 10,407,457) comes due Mar 10, 2027. Unpaid by Sep 10, 2027, it lapses early.
  • 1 fee due Nov 14, 2027
    The maintenance fee for Pyrrolopyrimidine Nucleosides and Analogs Thereof (US 11,981,700) comes due Nov 14, 2027. Unpaid by May 15, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.

Showing 1 to 9 of 9

Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 8,993,542Methods of Treating Viral Infections
In force
 · High confidence
In forceHigh confidence
US 9,006,218Nucleoside Phosphonate Salts
In force
 · High confidence
In forceHigh confidence
US 9,956,239Methods of Treating Retroviral Infections and Related Dosage Regimes
In force
 · Medium confidence
In forceMedium confidence
US 9,701,706Pyrrolopyrimidine Nucleosides and Analogs Thereof
In force
 · High confidence
In forceHigh confidence
US 9,708,359Pyrrolopyrimidine Nucleosides and Analogs Thereof
In force
 · Medium confidence
In forceMedium confidence
US 10,407,457Pyrrolopyrimidine Nucleosides and Analogs Thereof
In force
 · Medium confidence
In forceMedium confidence
US 10,941,175Pyrrolopyrimidine Nucleosides and Analogs Thereof
In force
 · Medium confidence
In forceMedium confidence
US 11,981,700Pyrrolopyrimidine Nucleosides and Analogs Thereof
In force
 · High confidence
In forceHigh confidence
US 11,111,264MORPHIC FORMS OF 4-Amino-7-(3,4-Dihydroxy-5-(HYDROXYMETHYL)TETRAHYDROFURAN-2-YL)-2-Methyl-7H-PYRROLO[2,3-d]PYRIMIDINE-5-Carboxamide AND USES THEREOF
In force
 · High confidence
In forceHigh confidence
Also on record, not counted in the 9: 24 patents in force now held by others · 5 lapsed for an unpaid fee · 12 ended at full term. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

5 pending · 5 abandoned · 17 no status recorded

Showing 1 to 10 of 27, newest filing first. An application has no patent term. A term is computed when and if it grants, and appears on that patent's own page. Where no title is shown, the bulk publication record carries none and this site holds no USPTO file history for that application.

ApplicationTitleFiledStatus
19/079,1517-BENZYL-4-(METHYLBENZYL)-2,4,6,7,8,9-HEXAHYDROIMIDAZO[1,2-A]PYRIDO[3,4-E] PYRIMIDIN-5 (1 H)-One, Salts Thereof and Methods of Using the Same in Combination TherapyMar 13, 2025Pending
19/027,475MORPHIC FORMS OF 4-AMINO-7-(3,4-DIHYDROXY-5-(HYDROXYMETHYL)TETRAHYDROFURAN-2-YL)-2-METHYL-7H-PYRROLO[2,3-d]PYRIMIDINE-5-CARBOXAMIDE AND USES THEREOFJan 17, 2025Pending
18/979,5677-Benzyl-4-(2-Methylbenzyl)-2,4,6,7,8,9-Hexahydroimidazo[1,2-a]PYRIDO[3,4-E] PYRIMIDIN-5 (1 H)-ONE, ANALOGS THEREOF, AND SALTS THEREOF AND METHODS FOR THEIR USE IN THERAPYDec 12, 2024Pending
18/609,391Pyrrolopyrimidine Nucleosides and Analogs ThereofMar 19, 2024Abandoned
18/603,0757-BENZYL-4-(2-METHYLBENZYL)-2,4,6,7,8,9-HEXAHYDROIMIDAZ0[1,2-A]PYRID0[3,4-E] PYRIMIDIN-5 (1 H)-One, Analogs Thereof, and Salts Thereof and Methods for Their Use in TherapyMar 12, 2024Pending
18/429,350Jan 31, 2024No status recorded
18/354,860Jul 19, 2023No status recorded
18/559,992Uses and Methods for Recurrent Primary CNS NeoplasmsMay 13, 2022Pending
18/553,144Pyrrolopyrimidine Nucleosides for Treating or Preventing a SARS-COV-2 InfectionMar 29, 2022Abandoned
17/393,496Aug 4, 2021No status recorded
10 of 27 applications shown.
Pro members see all 27 published applications.
Pro members: see all 27 applications
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited